Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lowe

Showing results (351-360 of 378) with videos related to

Pageof 38
Sort By:
The Journal of Emergency Medicine|January 14, 2023
Impact of Race and Ethnicity on Emergency Medical Services Administration of Opioid Pain Medications for Injured ChildrenDaniel K Nishijima, Daniel J Tancredi, Kathleen M Adelgais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2020
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III TrialRichard T Penson, Ricardo Villalobos Valencia, David Cibula, et al.
Pediatric Emergency Care|May 22, 2025
Racial and Ethnic Differences in ED Analgesia Among Injured Children Transported Via EMSSarahjean Kerolle, Lorin R Browne, Ruta Brazauskas, et al.
Gynecologic Oncology|November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancerKatherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.
Cancer Gene Therapy|June 10, 2006
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status reportJ S Norris, A Bielawska, T Day, et al.
Circulation|August 10, 2011
Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitroHiroshi Watanabe, Tao Yang, Dina Myers Stroud, et al.
The Journal of Infectious Diseases|November 14, 1997
Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeastR S Lowe, D R Brown, J T Bryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2024
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival ResultsGiovanni Scambia, Ricardo Villalobos Valencia, Nicoletta Colombo, et al.
The Lancet. Oncology|October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trialSusana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.
The Lancet. Oncology|December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialAmit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Pageof 38

Showing results (351-360 of 378) with videos related to

Sort By:
Pageof 38
The Journal of Emergency Medicine|January 14, 2023
Impact of Race and Ethnicity on Emergency Medical Services Administration of Opioid Pain Medications for Injured ChildrenDaniel K Nishijima, Daniel J Tancredi, Kathleen M Adelgais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2020
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III TrialRichard T Penson, Ricardo Villalobos Valencia, David Cibula, et al.
Pediatric Emergency Care|May 22, 2025
Racial and Ethnic Differences in ED Analgesia Among Injured Children Transported Via EMSSarahjean Kerolle, Lorin R Browne, Ruta Brazauskas, et al.
Gynecologic Oncology|November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancerKatherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.
Cancer Gene Therapy|June 10, 2006
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status reportJ S Norris, A Bielawska, T Day, et al.
Circulation|August 10, 2011
Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitroHiroshi Watanabe, Tao Yang, Dina Myers Stroud, et al.
The Journal of Infectious Diseases|November 14, 1997
Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeastR S Lowe, D R Brown, J T Bryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2024
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival ResultsGiovanni Scambia, Ricardo Villalobos Valencia, Nicoletta Colombo, et al.
The Lancet. Oncology|October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trialSusana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.
The Lancet. Oncology|December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialAmit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Pageof 38